Technology

In 2020, AI will become pervasive in enterprise applications and embedded within specific commercial workflows, writes Paul Shawah.

Having invested heavily in new regulatory database systems, life sciences firms owe it to themselves to capitalize on the insights locked within those rich data assets, writes David Gwyn.

How successful commercial teams will balance the continued shift toward personalized medicine and the increased concentration on data privacy.

Chris Moore looks at how a more interconnected and dynamic healthcare ecosystem will lead to safer and better outcomes.

With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success.

Goals for IDMP in Europe must not be diluted in 2020, if standardized medicinal product data is to be of tangible real-world benefit, says Remco Munnik.

Kellie Rademacher identifies some of the key questions to consider when choosing an AI partner.

Sandy Jennings asks: Why is the data you need never in the place you need it to be in?

Graham Francis sets out 5 critical business drivers for building a global enterprise labelling strategy over the year ahead.

How machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.

Organizations need to be correctly set up to deploy AI and machine learning. A new approach to processes and content is often required, write Jan van den Burg and Abid Rahman.

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

Technology grabbing the attention of watchful industry

Amid new findings on today’s C-suite mood and approach to digital transformation, experts-in a panel discussion and wider examinations by Pharm Exec editors-explore the intersection of data and technology and the areas that must evolve to meet the digital health demands of tomorrow.

Despite the buzz, physicians have limited familiarity and understanding with the burgeoning category of nucleic acid-based therapies, writes Meghan Oates-Zalesky.

Most emerging pharma companies still struggle to amass the computing power and assemble the teams to make use of the vast amounts of data now available to them, write Beth Beghou and Patrick Lezark.

In comparison with other industries, the use of AI is modest in life sciences. However, even within life sciences, adoption of AI in regulated environments, such as in the R&D value chain, is further behind. Sivakumar Thiagarajan

Mike Kean and Billy Tamulynas discuss the key components of growth-ready technology for early-stage pharma companies and how to make optimal use of them.

Getting real about the R&D capabilities required to win in the gene therapy space.

AI has huge potential, but the key to ROI is in the application, writes Alan White.

With a growing abundance of clinical and health information now available and achievable, the need for industry to apply common structures and rules to interpret and act on this data is critical.

Realizing the full potential of enabling technologies such as AI and machine learning in measuring treatment value and outcomes.

In keeping pace with the digital transformation, pharma companies are doing pretty well with data and infrastructure, but a fundamental reshaping of operating models remains the biggest hurdle to moving forward.

While commercial websites can employ analytics to gain better snapshots of their visitors, pharma faces far greater challenges in using technology as a way to track and understand its consumers.

Pharm Exec speaks to Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja about the growing practice of applying AI and machine learning in value-based and outcomes-based contracts.

The importance of KOIs in tapping into today’s market mindset.

The key steps to evading automation-fueled data crises.

William Golden, founder, chairman and CEO of Noveome Biotherapeutics, talks about the potential of the company's lead product, ST266.

Sathyanarayanan Krishnamurthy looks at the potential impact of Pharma 4.0 on product development and regulatory operations.

Biopharma companies hungry for digital talent must evaluate their real estate portfolio and workplace strategies to access new talent pools, says Joanne Henderson.